HLX-301

N/A

Report date: 2022/07/14 20:00:44

Base Information

Drug NameHLX-301
Drug Alias NameHLX-301
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionT cell immunoglobulin and ITIM domains inhibitorsProgrammed death-ligand 1 blockers
TargetsT cell immunoglobulin and ITIM domainsProgrammed death-ligand 1
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisSmall Cell Lung Carcinoma +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Henlius Biologics Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Henlius Biologics Co LtdShanghai Henlius Biotech Inc
Inactive CompaniesShanghai Henlius Biopharmaceuticals Co Ltd
Active IndicationsSolid tumoursNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[4] 
Inactive IndicationsSmall Cell Lung CarcinomaEsophageal NeoplasmsSquamous Cell Carcinoma of Head and Neck +[4] 

Other Information

ATC CodeN/A
Related LinksN/A